SEATTLE--(BUSINESS WIRE)--Jan. 24, 2006--Targeted Genetics Corporation (Nasdaq:TGEN) announced today the restructuring of its operations to reduce expenses and realign resources to advance its lead product candidate, tgAAC94, through clinical trials as quickly as possible. tgAAC94 is the Company’s anti tumor necrosis factor alpha (TNF-a), product candidate for the treatment of inflammatory arthritis.
